Paraoxonase 1 gene polymorphisms in patients with osteonecrosis of the femoral head with and without cerebral white matter lesions

Journal of Orthopaedic Research

Volumn 25, Issue 8, 2007, Pages 1087-1093

  Hadjigeorgiou, Georgios M ^a   Malizos, Konstantinos ^a   Dardiotis, Efthimios ^a   Aggelakis, Konstantinos ^a   Dardioti, Maria ^a   Zibis, Aristidis ^a   Dimitroulias, Apostolos ^a   Scarmeas, Nikolaos ^b   Tsezou, Aspasia ^a   Karantanas, Apostolos ^c  

^a UNIVERSITY OF THESSALY   (Greece)

^b NewYork Presbyterian Hospital   (United States)

^c GENERAL HOSPITAL OF LARISSA   (Greece)

Author keywords

Osteonecrosis; Paraoxonase 1; Polymorphism; White matter lesions

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FEMUR HEAD NECROSIS; GENE DOSAGE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOTYPE; HIGH RISK PATIENT; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; ONSET AGE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; WHITE MATTER;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; ARYLDIALKYLPHOSPHATASE; BRAIN DISEASES; CEREBRAL CORTEX; FEMALE; FEMUR HEAD NECROSIS; GENOTYPE; HUMANS; LIPIDS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 34547814093     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20393     Document Type: Article

References (39)

1. Mackness MI, Mackness B, Durrington PN, et al. 1998. Paraoxonase and coronary heart disease. Curr Opin Lipidol 9:319-324.
2. Davies HG, Richter RJ, Keifer M, et al. 1996. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14:334-336.
3. Durrington PN, Mackness B, Mackness MI. 2001. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473-480.
4. Mackness MI, Arrol S, Mackness B, et al. 1997. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet 349:851-852.
5. Schmidt R, Enzinger C, Ropele S, et al. 2003. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet 361:2046-2048.
6. Schmidt R, Schmidt H, Fazekas F, et al. 2000. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: three-year follow-up of the Austrian stroke prevention study. Arterioscler Thromb Vasc Biol 20:1811-1816.
7. Hadjigeorgiou GM, Karantanas AH, Zibis A, et al. 2004. Increased frequency of white matter lesions in patients with osteonecrosis (WMLeOn) of the femoral head. Eur J Radiol 50:278-284.
8. ARCO. 1992. Association Research Circulation Osseous: Committee of terminology and classification. ARCO News 4:41-46.
9. Motti C, Dessi M, Gnasso A, et al. 2001. A multiplex PCR-based DNA assay for the detection of paraoxonase gene cluster polymorphisms. Atherosclerosis 158:35-40.
10. Boehringer S, Epplen JT, Krawczak M. 2000. Genetic association studies of bronchial asthma - a need for Bonferroni correction? Hum Genet 107:197.
11. Sankoh AJ, Huque MF, Dubey SD. 1997. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 16:2529-2542.
12. Allebrandt KV, Souza RL, Chautard-Freire-Maia EA. 2002. Variability of the paraoxonase gene (PON1) in Euro-and Afro-Brazilians. Toxicol Appl Pharmacol 180:151-156.
13. Zintzaras E, Hadjigeorgiou GM. 2004. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. J Hum Genet 49:474-481.
14. Assouline-Dayan Y, Chang C, Greenspan A, et al. 2002. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32:94-124.
15. Korompilias AV, Ortel TL, Urbaniak JR. 2004. Coagulation abnormalities in patients with hip osteonecrosis. Orthop Clin North Am 35:265-271, vii.
16. Zalavras C, Dailiana Z, Elisaf M, et al. 2000. Potential aetiological factors concerning the development of osteonecrosis of the femoral head. Eur J Clin Invest 30:215-221.
17. Glueck CJ, Freiberg RA, Fontaine RN, et al. 2001. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res (386):19-33.
18. Zalavras CG, Vartholomatos G, Dokou E, et al. 2004. Genetic background of osteonecrosis: associated with thrombophilic mutations? Clin Orthop (422):251-255.
19. Mackness B, Mackness MI, Arrol S, et al. 1997. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 122:265-268.
20. Yamada Y, Ando F, Niino N, et al. 2003. Association of polymorphisms of paraoxonase 1 and 2 genes, alone or in combination, with bone mineral density in community-dwelling Japanese. J Hum Genet 48:469-475.
21. Compston JE, Vedi S, Stephen AB, et al. 1999. Reduced bone formation after exposure to organophosphates. Lancet 354:1791-1792.
22. Blain PG. 2001. Adverse health effects after low level exposure to organophosphates. Occup Environ Med 58: 689-690.
23. Pilkington A, Buchanan D, Jamal GA, et al. 2001. An epidemiological study of the relations between exposure to organophosphate pesticides and indices of chronic peripheral neuropathy and neuropsychological abnormalities in sheep farmers and dippers. Occup Environ Med 58:702-710.
24. Cooper GS, Miller FW, Germolec DR. 2002. Occupational exposures and autoimmune diseases. Int Immunopharmacol 2:303-313.
25. Landtblom AM, Flodin U, Soderfeldt B, et al. 1996. Organic solvents and multiple sclerosis: a synthesis of the current evidence. Epidemiology 7:429-433.
26. Lundberg I, Alfredsson L, Plato N, et al. 1994. Occupation, occupational exposure to chemicals and rheumatological disease. A register based cohort study. Scand J Rheumatol 23:305-310.
27. Rodgers KE. 1997. Effects of oral administration of malathion on the course of disease in MRL-1pr mice. J Autoimmun 10:367-373.
28. Tektonidou MG, Malagari K, Vlachoyiannopoulos PG, et al. 2003. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum 48:732-736.
29. Abu-Shakra M, Buskila D, Shoenfeld Y. 2003. Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol 25:13-24.
30. Ranade K, Kirchgessner TG, Iakoubova OA, et al. 2005. Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke 36:2346-2350.
31. Voetsch B, Benke KS, Panhuysen CI, et al. 2004. The combined effect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults. Arch Neurol 61:351-356.
32. Murata M, Maruyama T, Suzuki Y, et al. 2004. Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in type 2 diabetes mellitus. Diabet Med 21:837-844.
33. Murata M, Nakagawa M, Takahashi S. 1998. Molecular variant of the human paraoxonase/arylesterase gene is associated with central retinal vein occlusion in the Japanese population. Ophthalmologica 212:257-259.
34. Bradshaw G, Gutierrez A, Miyake JH, et al. 2005. Facilitated replacement of Kupffer cells expressing a paraoxonase-1 transgene is essential for ameliorating atherosclerosis in mice. Proc Natl Acad Sci USA 102: 11029-11034.
35. Ferre N, Marsillach J, Camps J, et al. 2006. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol 45:51-59.
36. Zalavras C, Shah S, Birnbaum MJ, et al. 2003. Role of apoptosis in glucocorticoid-induced osteoporosis and osteonecrosis. Crit Rev Eukaryot Gene Expr 13:221-235.
37. Weinstein RS, Nicholas RW, Manolagas SC. 2000. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 85:2907-2912.
38. Hattersley AT, McCarthy MI. 2005. What makes a good genetic association study? Lancet 366:1315-1323.
39. Devlin B, Roeder K. 1999. Genomic control for association studies. Biometrics 55:997-1004.